NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hund ...

If you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Jones Financial Companies Lllp increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by ...

Cantor Fitzgerald issued their FY2025 EPS estimates for Intellia Therapeutics in a research report issued on Monday, March 17th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company ...

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA ...

On Tuesday, 11 March 2025, Intellia Therapeutics (NASDAQ: NTLA) presented at the Barclays 27th Annual Global Healthcare Conference, sharing strategic insights into its groundbreaking genomic ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...